Cochlear gene therapy : Current Opinion in Neurology Cochlear gene therapy : Current Opinion
in Neurology Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts …

A number of genes are reportedly responsible for hereditary hearing loss, which accounts
for over 50% of all congenital hearing loss cases. Recent advances in genetic testing have …

Despite the prevalence of hearing disorders in humans, therapeutic options are limited to
rehabilitation with amplification or implantable electronic prosthesis. In contrast to …

Gene therapies for hearing loss are expected to enter clinical trials in the immediate future.
To provide referral for appropriate trials and counseling regarding benefits of genetic …

Over 450 million people worldwide suffer from hearing loss, leading to an estimated
economic burden of∼ $750 billion. The past decade has seen significant advances in the …

Gene therapy has considerable potential for the treatment of disorders of the inner ear. Many
forms of inherited hearing loss have now been linked to specific locations in the genome …

Sensorineural hearing loss (SNHL) is the most common sensory disorder. Its underlying
etiologies include a broad spectrum of genetic and environmental factors that can lead to …

Sensorineural hearing loss (SNHL) affects millions of people. Genetic mutations play a large
and direct role in both congenital and late-onset cases of SNHL (eg, age-dependent hearing …

More than 15 years have passed since the official completion of the Human Genome
Project. Predominantly due to this project, over one hundred genes have now been linked to …

Congenital hearing loss (HL) affects about 1 in every 500 infants. Among those affected
more than half are caused by genetic mutations. According to the cellular sites affected by …